Figure 1.

Frequency of best overall response to immune checkpoint inhibitors (ICIs) after acquired resistance to EGFR‐TKI treatment in patients with EGFR‐mutated NSCLC. Frequency of best overall response to ICIs for all patients (N = 27) (A), patients with common EGFR mutations (N = 20) (B), and patients with uncommon EGFR mutations (N = 7) (C) are shown in the pie chart. ICI, immune checkpoint inhibitor; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; NSCLC, non‐small cell lung cancer